{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:39Z","timestamp":1792787919205,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04971-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:41:16Z","timestamp":1792741276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protective effect of N-acetylcysteine on oxaliplatin-induced peripheral neuropathy in colorectal cancer: a randomized controlled trial"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5947-4882","authenticated-orcid":false,"given":"Zeyad K.","family":"Hegazy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar K.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal M.","family":"Elmashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"9","key":"4971_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/1389450121999201117115717","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Elshiwy K, Elkeraie Y et al (2021) Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets 22(9):998\u20131009. https:\/\/doi.org\/10.2174\/1389450121999201117115717","journal-title":"Curr Drug Targets"},{"issue":"2","key":"4971_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.giec.2021.12.008","volume":"32","author":"JA Sninsky","year":"2022","unstructured":"Sninsky JA, Shore BM, Lupu GV et al (2022) Risk Factors for Colorectal Polyps and Cancer. Gastrointest Endosc Clin N Am 32(2):195\u2013213. https:\/\/doi.org\/10.1016\/j.giec.2021.12.008","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"5","key":"4971_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.21037\/jgo.2019.07.03","volume":"10","author":"LG Kogan","year":"2019","unstructured":"Kogan LG, Davis SL, Brooks GA (2019) Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: a multicenter retrospective analysis. J Gastrointest Oncol 10(5):841\u2013846. https:\/\/doi.org\/10.21037\/jgo.2019.07.03","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"4971_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","volume":"18","author":"T Alcindor","year":"2011","unstructured":"Alcindor T, Beauger N (2011) Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 18(1):18\u201325. https:\/\/doi.org\/10.3747\/co.v18i1.708","journal-title":"Curr Oncol"},{"issue":"9","key":"4971_CR5","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00415-020-09942-w","volume":"268","author":"L Kang","year":"2021","unstructured":"Kang L, Tian Y, Xu S et al (2021) Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol 268(9):3269\u20133282. https:\/\/doi.org\/10.1007\/s00415-020-09942-w","journal-title":"J Neurol"},{"key":"4971_CR6","doi-asserted-by":"publisher","unstructured":"Cavaletti G, Marmiroli P (2020) Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers (Basel) 12(6). https:\/\/doi.org\/10.3390\/cancers12061370","DOI":"10.3390\/cancers12061370"},{"issue":"7","key":"4971_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00520-024-08627-8","volume":"32","author":"D Balayssac","year":"2024","unstructured":"Balayssac D, Kerckhove N, Selvy M et al (2024) Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life. Support Care Cancer 32(7):427. https:\/\/doi.org\/10.1007\/s00520-024-08627-8","journal-title":"Support Care Cancer"},{"issue":"30","key":"4971_CR8","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/jco.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK et al (2015) Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol 33(30):3416\u20133422. https:\/\/doi.org\/10.1200\/jco.2014.58.8533","journal-title":"J Clin Oncol"},{"key":"4971_CR9","doi-asserted-by":"publisher","unstructured":"Kerckhove N, Collin A, Cond\u00e9 S et al (2017) Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. https:\/\/doi.org\/10.3389\/fphar.2017.00086. Front Pharmacol.886","DOI":"10.3389\/fphar.2017.00086"},{"issue":"6","key":"4971_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471\u20131474. https:\/\/doi.org\/10.1245\/s10434-010-0985-4","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4971_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","volume":"2","author":"A Areti","year":"2014","unstructured":"Areti A, Yerra VG, Naidu V et al (2014) Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox biol 2(1):289\u2013295","journal-title":"Redox biol"},{"key":"4971_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00174","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I (2017) Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 10174. https:\/\/doi.org\/10.3389\/fnmol.2017.00174","journal-title":"Front Mol Neurosci 10174"},{"key":"4971_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.03.019","author":"L Di Cesare Mannelli","year":"2013","unstructured":"Di Cesare Mannelli L, Zanardelli M, Failli P et al (2013) Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy? Free Radic Biol Med. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.03.019. .61143-50","journal-title":"Free Radic Biol Med"},{"key":"4971_CR14","doi-asserted-by":"publisher","unstructured":"Leelarungrayub D, Khansuwan R, Pothongsunun P et al (2011) N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men. Oxid Med Cell Longev 2011329643. https:\/\/doi.org\/10.1155\/2011\/329643","DOI":"10.1155\/2011\/329643"},{"key":"4971_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1642552","author":"M Salama","year":"2025","unstructured":"Salama M, Barnes D, Georghiou A et al (2025) Anti-oxidative stress therapies prevent severe chemotherapy-induced peripheral neuropathy in colorectal cancer patients treated with oxaliplatin: a systematic review and meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2025.1642552. 151642552","journal-title":"Front Oncol"},{"issue":"45","key":"4971_CR16","doi-asserted-by":"publisher","first-page":"e13087","DOI":"10.1097\/md.0000000000013087","volume":"97","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ju Y, Ma Y et al (2018) N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Med (Baltim) 97(45):e13087. https:\/\/doi.org\/10.1097\/md.0000000000013087","journal-title":"Med (Baltim)"},{"key":"4971_CR17","doi-asserted-by":"publisher","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W et al (2019) Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 20(6). https:\/\/doi.org\/10.3390\/ijms20061451","DOI":"10.3390\/ijms20061451"},{"issue":"6","key":"4971_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12640-025-00775-x","volume":"43","author":"S Dehghani","year":"2025","unstructured":"Dehghani S, Khorsandi H, Hosseinzadegan R et al (2025) Neuroinflammatory Mechanisms and Therapeutic Targets in Oxaliplatin-Induced Peripheral Neuropathy: a Comprehensive Review. Neurotox Res 43(6):52. https:\/\/doi.org\/10.1007\/s12640-025-00775-x","journal-title":"Neurotox Res"},{"key":"4971_CR19","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhu BT (2025) Role of protein disulfide isomerase in mediating sulfasalazine-induced ferroptosis in HT22 cells: The PDI\u2009\u2013\u2009NOS\u2013NO\u2009\u2013\u2009ROS\/lipid-ROS cascade. Archives of Biochemistry and Biophysics.768110366.","DOI":"10.1016\/j.abb.2025.110366"},{"issue":"4","key":"4971_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1534735404270335","volume":"3","author":"KA Conklin","year":"2004","unstructured":"Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr cancer Ther 3(4):294\u2013300","journal-title":"Integr cancer Ther"},{"key":"4971_CR21","doi-asserted-by":"publisher","unstructured":"Campolo M, Lanza M, Paterniti I et al (2021) PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-\u03baB\/Nrf-2 Axis. Int J Mol Sci 22(8). https:\/\/doi.org\/10.3390\/ijms22083927","DOI":"10.3390\/ijms22083927"},{"issue":"2","key":"4971_CR22","first-page":"140","volume":"44","author":"B Purwanto","year":"2012","unstructured":"Purwanto B, Prasetyo DH (2012) Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients. Acta Med Indones 44(2):140\u2013144","journal-title":"Acta Med Indones"},{"issue":"10","key":"4971_CR23","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","volume":"27","author":"PR Dobner","year":"2006","unstructured":"Dobner PR (2006) Neurotensin and pain modulation. Peptides 27(10):2405\u20132414","journal-title":"Peptides"},{"key":"4971_CR24","doi-asserted-by":"crossref","unstructured":"Kim H-E, Hong JH (2018) The overview of channels, transporters, and calcium signaling molecules during amelogenesis. Arch Oral Biol. 9347\u20139355","DOI":"10.1016\/j.archoralbio.2018.05.014"},{"issue":"8","key":"4971_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1097\/j.pain.0000000000000575","volume":"157","author":"J Li","year":"2016","unstructured":"Li J, Xu L, Deng X et al (2016) N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain 157(8):1711\u20131723. https:\/\/doi.org\/10.1097\/j.pain.0000000000000575","journal-title":"Pain"},{"issue":"4","key":"4971_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3344\/kjp.2020.33.4.318","volume":"33","author":"M Yin","year":"2020","unstructured":"Yin M, Kim YO, Choi JI et al (2020) Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain 33(4):318\u2013325. https:\/\/doi.org\/10.3344\/kjp.2020.33.4.318","journal-title":"Korean J Pain"},{"issue":"3","key":"4971_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","volume":"157","author":"L Ventzel","year":"2016","unstructured":"Ventzel L, Jensen AB, Jensen AR et al (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560\u2013568. https:\/\/doi.org\/10.1097\/j.pain.0000000000000404","journal-title":"Pain"},{"issue":"8","key":"4971_CR28","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","volume":"1830","author":"Y Samuni","year":"2013","unstructured":"Samuni Y, Goldstein S, Dean OM et al (2013) The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 1830(8):4117\u20134129. https:\/\/doi.org\/10.1016\/j.bbagen.2013.04.016","journal-title":"Biochim Biophys Acta"},{"key":"4971_CR29","doi-asserted-by":"publisher","unstructured":"Ten\u00f3rio M, Graciliano NG, Moura FA et al (2021) N-Acetylcysteine (NAC): Impacts on Human Health. Antioxid (Basel) 10(6). https:\/\/doi.org\/10.3390\/antiox10060967","DOI":"10.3390\/antiox10060967"},{"issue":"8","key":"4971_CR30","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1570159x19666201230144109","volume":"19","author":"G Raghu","year":"2021","unstructured":"Raghu G, Berk M, Campochiaro PA et al (2021) The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol 19(8):1202\u20131224. https:\/\/doi.org\/10.2174\/1570159x19666201230144109","journal-title":"Curr Neuropharmacol"},{"key":"4971_CR31","doi-asserted-by":"publisher","unstructured":"Tardiolo G, Bramanti P, Mazzon E (2018) Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules 23(12). https:\/\/doi.org\/10.3390\/molecules23123305","DOI":"10.3390\/molecules23123305"},{"issue":"7","key":"4971_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00011-011-0323-8","volume":"60","author":"J Palacio","year":"2011","unstructured":"Palacio J, Markert U, Mart\u00ednez P (2011) Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res 60(7):695\u2013704","journal-title":"Inflamm Res"},{"issue":"7","key":"4971_CR33","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1177\/1078155219900788","volume":"26","author":"N Bondad","year":"2020","unstructured":"Bondad N, Boostani R, Barri A et al (2020) Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial. J Oncol Pharm Pract 26(7):1575\u20131582. https:\/\/doi.org\/10.1177\/1078155219900788","journal-title":"J Oncol Pharm Pract"},{"key":"4971_CR34","doi-asserted-by":"publisher","unstructured":"Askari M, Faryabi R, Mozaffari H et al (2020) The effects of N-Acetylcysteine on serum level of inflammatory biomarkers in adults. Findings from a systematic review and meta-analysis of randomized clinical trials. https:\/\/doi.org\/10.1016\/j.cyto.2020.155239. Cytokine.135155239","DOI":"10.1016\/j.cyto.2020.155239"},{"key":"4971_CR35","doi-asserted-by":"publisher","unstructured":"Borgstr\u00f6m L, K\u00e5gedal B, Paulsen O (1986) Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31(2):217-22 https:\/\/doi.org\/10.1007\/BF00606662","DOI":"10.1007\/BF00606662"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04971-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04971-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:01:35Z","timestamp":1792785695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04971-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4971"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04971-0","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was performed in compliance with the 1964 Helsinki Declaration\u2019s ethical guidelines and its subsequent revisions. This trial received approval from the Research Ethics Committee of Tanta University and is registered on ClinicalTrials.gov (ID: NCT07391163). The advantages and dangers of the study were explained to each participant.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"124"}}